Cannabinoid Research & Development

Cannabinoid Research & Development (CRD) was a Jamaican-based biotechnology company and a subsidiary of United Cannabis Corporation, focused on advancing medical cannabis therapies through biomedical research. The company specialized in genetic restoration, cannabinoid isolation techniques, and the development of phyto-therapeutic products for the pharmaceutical and nutraceutical industries. Its primary product line, the Prana Bio Nutrient Medicinals, included various formulations such as capsules, sublinguals, and topicals designed to target the endocannabinoid system for conditions like chronic pain and neuropathy. CRD established significant infrastructure in Jamaica for cultivation and research, including clinical trials conducted in partnership with the University of the West Indies. Following the bankruptcy filing of its parent company, United Cannabis Corporation, in 2020, the entity's operations have largely ceased.